Preclinical News and Research

RSS

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

6 Dec 2013

New project aims to reduce animal testing for drug development

Researchers at the University of East Anglia are launching a new project to develop methods which could one-day decrease the use of rats and mice in pharmaceutical testing.

6 Dec 2013

Researchers take closer look at genetically engineered mouse models and human cancer samples

Researchers from the Fred Hutchinson Cancer Research Center in Seattle, WA have taken a closer look at existing mouse models of cancer, specifically comparing them to human cancer samples. These genetically engineered mouse models (which usually either overexpress a cancer-causing gene-or "oncogene"-or carry a deletion for a "tumor suppressor" gene) have been extensively used to understand human cancer biology in studies of drug resistance, early detection, metastasis, and cancer prevention, as well as for the preclinical development of novel targeted therapeutics.

6 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

Type 2 diabetes management: an interview with Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

The rate of Type 2 Diabetes is rapidly increasing, particularly in Asian countries which make up more than 60 percent of the world’s diabetes population. So it’s really important physicians feel confident managing this chronic condition in their daily clinical practice.

5 Dec 2013

B2G2 component of grape seed extract induces apoptosis in prostate cancer cells

A University of Colorado Cancer Center study published online ahead of print in the journal Nutrition and Cancer describes the laboratory synthesis of the most active component of grape seed extract, B2G2, and shows this synthesized compound induces the cell death known as apoptosis in prostate cancer cells while leaving healthy cells unharmed.

5 Dec 2013

Senesco completes cohort 3 of SNS01-T Phase 1b/2a trial for multiple myeloma and lymphoma treatment

Senesco Technologies, Inc. reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

A new approach for treating colorectal cancer

Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse.

4 Dec 2013

Mount Sinai cardiologists contribute to the creation of new cardiomyopathy classification system

Leading cardiologists at The Mount Sinai Hospital have contributed to the development of a new classification system called MOGE(S) for cardiomyopathies, the diseases of the heart muscle which can lead to heart enlargement and heart failure.

4 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

3T MRI scanner allows Polish scientists to perform structural and functional imaging of human brain

The Nencki Institute of Experimental Biology in Warsaw launches research programs, which require state-of-the-art magnetic resonance scanner.

3 Dec 2013

IRCM researcher sheds light on inconsistencies between pharmacogenomic studies

A bioinformatics expert at the IRCM, Benjamin Haibe-Kains, recently published an article stressing the importance of standardizing drug screening studies in the prestigious scientific journal Nature. The study supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.

3 Dec 2013

EMD Serono's TocopheRx to focus on development of oral FSH agonists for infertility treatment

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today the creation of TocopheRx, a Boston-based spin-off company resulting from the Entrepreneur Partnership Program launched by Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, in April 2012.

3 Dec 2013

JHL Biotech installs GE Healthcare's FlexFactory biomanufacturing platform at Hsinchu plant in Taiwan

GE Healthcare Life Sciences and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory biomanufacturing platform at JHL Biotech's Research Center and manufacturing plant in Hsinchu, Taiwan.

2 Dec 2013

Researchers discover promising new approach for colorectal cancer treatment

2 Dec 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

Preclinical News and Research

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

New project aims to reduce animal testing for drug development

Researchers take closer look at genetically engineered mouse models and human cancer samples

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Type 2 diabetes management: an interview with Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

B2G2 component of grape seed extract induces apoptosis in prostate cancer cells

Senesco completes cohort 3 of SNS01-T Phase 1b/2a trial for multiple myeloma and lymphoma treatment

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

A new approach for treating colorectal cancer

Mount Sinai cardiologists contribute to the creation of new cardiomyopathy classification system

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

3T MRI scanner allows Polish scientists to perform structural and functional imaging of human brain

IRCM researcher sheds light on inconsistencies between pharmacogenomic studies

EMD Serono's TocopheRx to focus on development of oral FSH agonists for infertility treatment

JHL Biotech installs GE Healthcare's FlexFactory biomanufacturing platform at Hsinchu plant in Taiwan

Researchers discover promising new approach for colorectal cancer treatment

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics